Acute Invasive AspergillosisTreatment Market Drivers
Rising incidence of various typesof cancers, is in turn expected to support growth of the global AcuteInvasive Aspergillosis Treatment Market. According to the Centers forDisease Control and Prevention, the epidemiology of invasive aspergillusinfection is dependent upon increasing number of solid organ transplants, stemcell transplant, and newer immunosuppressive agents, 2017. According to OrganProcurement and Transplantation Network (OPTN), around 8,500 organ transplantshave been performed in 2018 and the number is expected to grow in the nearfuture. These factors are expected to support the growth of the acute invasiveaspergillosis treatment market. Patients who undergo organ transplant procedureare often prescribed immunosuppressant medications, which increases theirsusceptibility to aspergillosis infection. Similarly, patients in the advancedstages of AIDS are also highly susceptible to opportunistic infections such asaspergillosis. According to the World Health Organization (WHO), around 36.7million people were found suffering from HIV in 2016. Extended use ofcorticosteroids further weakens the immune system, thus increasing the risk ofdeveloping such infections. This in turn, is increasing the demand for acuteinvasive aspergillosis treatment over the forecast period. According to BritishInfection Association, the high risk population for invasive aspergillosisincludes patients who have undergone allogeneic hematopoietic stem celltransplantation (HSCT), autologous HSCT patients, solid organ transplantpatients as well as AIDS patients, patients suffering from acute myeloidleukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia,non-Hodgkin lymphoma, and myeloma patients. According to WHO, Cancer is thesecond-leading cause of death globally, and the disease caused 8.8 milliondeaths in 2015.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1520
Acute Invasive Aspergillosis isan acute infection or fungal growth, which arises due to Aspergillus fungus.Almost everyone comes in contact with the Aspergillus fungus as it is found ondecaying vegetation and dead leaves, however, not everyone is susceptible tothe infection. Aspergillosis is categorized into various types such as invasiveaspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonaryaspergillosis, allergic aspergillus sinusitis, aspergilloma, and cutaneousaspergillosis. Active invasive aspergillosis (IA) is a rare, opportunistic, andserious fungal infection, which affects immunocompromised patients or thosesuffering from lung diseases. Risk factors responsible for the development ofinvasive aspergillosis infection include weakened immune system, low whiteblood cell count, presence of lung cavities, asthma or cystic fibrosis, andlong-term corticosteroid therapy. Commercially available drugs for thetreatment of aspergillus infection include Voriconazole, Capsofungin, andAmphotericin B, among others.
The U.S. Food & DrugAdministration (FDA) is increasingly approving several drugs for the treatmentof this infection. For instance, Isavuconazonium, a prodrug form ofIsavuconazole was approved by the FDA in 2015. Astellas Pharma US, Inc. marketsIsavuconazonium under the brand name Cresemba. Astellas Pharma partnered withBasilea Pharmaceutica International Ltd. for license, co-development, andco-promotion of Isavuconazole (Cresemba), in 2010. In 2014, BasileaPharmaceutica International Ltd. received full rights to sell Isavuconazole inall markets outside of the U.S. and Canada, and Astellas Pharma responsible forU.S. and Canada markets. Moreover, Basilea Pharmaceutica Ltd. partnered withAsahi Kasei Pharma for Isavuconazole development, licensing, and marketing inJapan (responsibility of Asahi Kasei), in 2016. The global acute invasiveaspergillosis treatment market is expected to be significantly impacted overthe forecast period as the drug Cresemba will expire in 2020. As genericmanufacturers enter the market, the prices are expected to drop and volumes areexpected to increase over the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/acute-invasive-aspergillosis-treatment-market-1520
However, drug resistance toantifungal medications is widely witnessed during treatment of aspergillosisinfections, which is expected to restrain growth of the acute invasiveaspergillosis treatment market over the forecast period.
Acute Invasive AspergillosisTreatment Market Insights
Most antifungal medications havelost their patent protection over the last few years and generic versions ofthese products are increasingly being made available by generic drugmanufacturers, which in turn is supporting growth of the acute invasiveaspergillosis treatment market. Manufacturers such as Amneal Pharmaceuticals,Sandoz Inc., Glenmark Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., andTeva Pharmaceuticals offer generic versions of antifungal medications in theacute invasive aspergillosis treatment market. Independent organizations arededicated towards research and development of novel antifungal therapies. Forinstance, F2G, an established U.K.-based biotechnology company is focused onthe discovery and development of novel drugs for the treatment of seriousfungal diseases such as acute invasive aspergillosis.
Key players operating in theglobal acute invasive aspergillosis treatment market include GlaxoSmithKline,Mylan Pharmaceuticals, Inc., Novartis AG, Abbott laboratories, Eli Lilly andCompany, AstraZeneca Plc, Pfizer, Inc., Johnson & Johnson, TakedaPharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica InternationalLtd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1520
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
